Validation of Prognostic Circulating Cell-Free RNA Biomarkers <i>HPGD</i>, <i>PACS1</i>, and <i>TDP2</i> in Colorectal Cancer Through TaqMan qPCR and Correlation Analysis
Circulating cell-free RNAs (cfRNAs) have emerged as promising non-invasive biomarkers for colorectal cancer (CRC), offering insights into the disease’s prognosis. This study investigates the prognostic significance of the specific cfRNA biomarkers <i>HPGD</i>, <i>PACS1</i>, a...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Current Issues in Molecular Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1467-3045/47/7/508 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Circulating cell-free RNAs (cfRNAs) have emerged as promising non-invasive biomarkers for colorectal cancer (CRC), offering insights into the disease’s prognosis. This study investigates the prognostic significance of the specific cfRNA biomarkers <i>HPGD</i>, <i>PACS1</i>, and <i>TDP2</i> by employing the Taqman quantitative PCR (qPCR) to evaluate their expression levels in a cohort of 52 CRC patients. The methodology involved a robust statistical analysis to assess correlations between cfRNA levels and clinical parameters, including survival rates and recurrence incidences. Findings revealed a significant upregulation in the expression of <i>HPGD</i> and <i>PACS1</i>, while <i>TDP2</i> displayed varying results, indicating a complex role in disease dynamics. Notably, lower expression levels of <i>HPGD</i> were associated with reduced survival, suggesting its potential as a negative prognostic indicator. Conversely, <i>TDP2</i> levels correlated strongly with increased risks of recurrence, highlighting its clinical relevance in monitoring disease progression. Overall, this study elucidates the intricate interplay between these cfRNAs in the CRC prognosis. The results advocate for further exploratory studies to validate <i>PACS1</i>’s potential as a prognostic marker and reinforce the clinical significance of <i>HPGD</i> and <i>TDP2</i> in the context of CRC management, positioning them as vital elements in the landscape of molecular oncology. |
|---|---|
| ISSN: | 1467-3037 1467-3045 |